LL-BM-781 α1a
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-03622 |
| CAS | 72380-10-0 |
| Molecular Weight | 1110.26 |
| Molecular Formula | C45H87N15O17 |
Online Inquiry
Description
It is originally isolated from Nocardia sp. BM 782Ce82 (NRRL 11239). LL-BM-781 α1a has anti-mycobacterium, gram-positive and negative activities.
Specification
| Synonyms | Antibiotic LL-BM-781 α1a |
Properties
| Appearance | White Powder |
| Antibiotic Activity Spectrum | Gram-positive bacteria; Gram-negative bacteria; mycobacteria |
| Solubility | Soluble in Water |
Reference Reading
1. Zebrafish as a Model System for the Study of Severe CaV2.1 (α1A) Channelopathies
Sidharth Tyagi, Angeles B Ribera, Roger A Bannister Front Mol Neurosci. 2020 Feb 7;12:329. doi: 10.3389/fnmol.2019.00329. eCollection 2019.
The P/Q-type CaV2.1 channel regulates neurotransmitter release at neuromuscular junctions (NMJ) and many central synapses. CACNA1A encodes the pore-containing α1A subunit of CaV2.1 channels. In humans, de novo CACNA1A mutations result in a wide spectrum of neurological, neuromuscular, and movement disorders, such as familial hemiplegic migraine type 1 (FHM1), episodic ataxia type 2 (EA2), as well as a more recently discovered class of more severe disorders, which are characterized by ataxia, hypotonia, cerebellar atrophy, and cognitive/developmental delay. Heterologous expression of CaV2.1 channels has allowed for an understanding of the consequences of CACNA1A missense mutations on channel function. In contrast, a mechanistic understanding of how specific CACNA1A mutations lead in vivo to the resultant phenotypes is lacking. In this review, we present the zebrafish as a model to both study in vivo mechanisms of CACNA1A mutations that result in synaptic and behavioral defects and to screen for effective drug therapies to combat these and other CaV2.1 channelopathies.
2. Cardiac α1A-adrenergic receptors: emerging protective roles in cardiovascular diseases
Jiandong Zhang, Paul C Simpson, Brian C Jensen Am J Physiol Heart Circ Physiol. 2021 Feb 1;320(2):H725-H733. doi: 10.1152/ajpheart.00621.2020. Epub 2020 Dec 4.
α1-Adrenergic receptors (ARs) are catecholamine-activated G protein-coupled receptors (GPCRs) that are expressed in mouse and human myocardium and vasculature, and play essential roles in the regulation of cardiovascular physiology. Though α1-ARs are less abundant in the heart than β1-ARs, activation of cardiac α1-ARs results in important biologic processes such as hypertrophy, positive inotropy, ischemic preconditioning, and protection from cell death. Data from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) indicate that nonselectively blocking α1-ARs is associated with a twofold increase in adverse cardiac events, including heart failure and angina, suggesting that α1-AR activation might also be cardioprotective in humans. Mounting evidence implicates the α1A-AR subtype in these adaptive effects, including prevention and reversal of heart failure in animal models by α1A agonists. In this review, we summarize recent advances in our understanding of cardiac α1A-ARs.
3. What makes the α1A -adrenoceptor gene product assume an α1L -adrenoceptor phenotype?
Carl W White, Edilson Dantas da Silva Junior, Linzi Lim, Sabatino Ventura Br J Pharmacol. 2019 Jul;176(14):2358-2365. doi: 10.1111/bph.14599. Epub 2019 Mar 27.
The α1A -adrenoceptor is abundantly expressed in the lower urinary tract and is the principal therapeutic target for the symptomatic treatment of lower urinary tract symptoms in men. Prazosin has a lower affinity for the lower urinary tract α1A -adrenoceptor than α1A -adrenoceptors found in other parts of the body. This has led to the lower urinary tract α1A -adrenoceptor being subclassified as an α1L -adrenoceptor. It was demonstrated that this pharmacologically distinct α1L -adrenoceptor is a product of the α1A -adrenoceptor gene, but the mechanism by which this altered phenotype is achieved remains a mystery. Hypotheses for this altered pharmacology include the presence of an interacting protein such as cysteine-rich with EGF-like domain (CRELD) 1 or other GPCRs such as the CXCR2 chemokine or 5-HT1B receptor. Alternatively, the influence of breast cancer resistance protein (BCRP) efflux transporters on the pharmacology of α1A -adrenoceptors has also been investigated. These and other hypotheses will be described and discussed in this review. LINKED ARTICLES: This article is part of a themed section on Adrenoceptors-New Roles for Old Players. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.14/issuetoc.
Recommended Products
| BBF-02642 | Lactonamycin | Inquiry |
| BBF-01829 | Deoxynojirimycin | Inquiry |
| BBF-03753 | Baicalin | Inquiry |
| BBF-00677 | 3-Amino-3-deoxy-D-glucose | Inquiry |
| BBF-02614 | Nystatin | Inquiry |
| BBF-05862 | Epirubicin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
